Piedra, A., Guinart-Cuadra, A., Martínez-Recio, S., Mulet, M., Zamora, C., Osuna-Gómez, R., . . . Majem, M. (2026). Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).
Citación estilo ChicagoPiedra, A., et al. Baseline PD-L1 Expression On Circulating Immune Cells As a Predictor of Survival and Immune-related Adverse Events in Extensive-stage Small-cell Lung Cancer Patients Treated With Durvalumab and Carboplatin-etoposide (NCT04712903 Trial). 2026.
Cita MLAPiedra, A., et al. Baseline PD-L1 Expression On Circulating Immune Cells As a Predictor of Survival and Immune-related Adverse Events in Extensive-stage Small-cell Lung Cancer Patients Treated With Durvalumab and Carboplatin-etoposide (NCT04712903 Trial). 2026.